前列腺动脉栓塞与经尿道前列腺电切术治疗良性前列腺增生:随机开放标签单中心试验2年结果
一项随机开放标签单中心试验纳入103例≥40岁难治性LUTS/BPO患者,比较PAE与TURP的2年疗效与安全性。结果显示TURP在IPSS、最大尿流率、残余尿和前列腺体积改善上均优于PAE,但PAE不良事件更少;PAE组21%患者2年内因疗效不佳需转TURP。
要点
- TURP在2年时对LUTS/BPO的症状和功能指标改善均优于PAE。
- PAE总体不良事件少于TURP,但严重程度分布相似。
- PAE组21%患者2年内因疗效不佳需转TURP,选择患者时应考虑此劣势。
核心结论
- PAE在2年时对LUTS/BPO的改善劣于TURP,且再治疗率相关。
- PAE并发症少于TURP,但功能结局的劣势应在患者选择和咨询中考虑。
研究设计与样本
- 随机、开放标签、单中心试验,纳入103例≥40岁难治性LUTS/BPO患者,比较PAE与TURP。
主要发现
- 2年IPSS平均下降PAE组9.21分,TURP组12.09分,差异2.88(95%CI 0.04-5.72;p=0.047)。
- 最大尿流率改善PAE组3.9 ml/s,TURP组10.23 ml/s,差异-6.33(-10.12至-2.54;p<0.001)。
- 残余尿减少PAE组62.1 ml,TURP组204.0 ml,差异141.91(43.31-240.51;p=0.005)。
- 前列腺体积减少PAE组10.66 ml,TURP组30.20 ml,差异19.54(7.70-31.38;p=0.005)。
- 不良事件总数PAE组43例次,TURP组78例次(p=0.005),严重程度分布相似。
关键数值与推荐
- 除勃起功能外,TURP在多数其他患者报告结局上也优于PAE。
- PAE组10例(21%)患者2年内因临床结局不满意需转TURP。
临床怎么用
- 对于难治性LUTS/BPO患者,选择PAE时应告知其症状和功能改善可能不如TURP,且再治疗风险较高。
- PAE可作为并发症风险较低的选择,但需结合患者对疗效的期望个体化决策。
局限性
- PAE组中10例(21%)因疗效不佳转TURP,导致其后续结局无法评估,构成研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostatic artery embolisation (PAE) for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction (LUTS/BPO) still remains under investigation. OBJECTIVE: To compare the efficacy and safety of PAE and transurethral resection of the prostate (TURP) in the treatment of LUTS/BPO at 2 yr of follow-up. DESIGN, SETTING, AND PARTICIPANTS: A randomised, open-label trial was conducted. There were 103 participants aged ≥40 yr with refractory LUTS/BPO. INTERVENTION: PAE versus TURP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: International Prostate Symptoms Score (IPSS) and other questionnaires, functional measures, prostate volume, and adverse events were evaluated. Changes from baseline to 2 yr were tested for differences between the two interventions with standard two-sided tests. RESULTS AND LIMITATIONS: The mean reduction in IPSS after 2 yr was 9.21 points after PAE and 12.09 points after TURP (difference of 2.88 [95% confidence interval 0.04-5.72]; p = 0.047). Superiority of TURP was also found for most other patient-reported outcomes except for erectile function. PAE was less effective than TURP regarding the improvement of maximum urinary flow rate (3.9 vs 10.23 ml/s, difference of -6.33 [-10.12 to -2.54]; p < 0.001), reduction of postvoid residual urine (62.1 vs 204.0 ml; 141.91 [43.31-240.51]; p = 0.005), and reduction of prostate volume (10.66 vs 30.20 ml; 19.54 [7.70-31.38]; p = 0.005). Adverse events were less frequent after PAE than after TURP (total occurrence n = 43 vs 78, p = 0.005), but the distribution among severity classes was similar. Ten patients (21%) who initially underwent PAE required TURP within 2 yr due to unsatisfying clinical outcomes, which prevented further assessment of their outcomes and, therefore, represents a limitation of the study. CONCLUSIONS: Inferior improvements in LUTS/BPO and a relevant re-treatment rate are found 2 yr after PAE compared with TURP. PAE is associated with fewer complications than TURP. The disadvantages of PAE regarding functional outcomes should be considered for patient selection and counselling. PATIENT SUMMARY: Prostatic artery embolisation is safe and effective. However, compared with transurethral resection of the prostate, its disadvantages regarding subjective and objective outcomes should be considered for individual treatment choices.
引用
- Abt D, Müllhaupt G, Hechelhammer L, et al. Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial. Eur Urol. 2021. PMID: 33612376. doi:10.1016/j.eururo.2021.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。